Skip to main content
SpringerLink
Log in

Antikörper gegen citrullinierte Peptidantigene in Klinik und Forschung

Antibodies against citrullinated peptides in clinical practice and research

  • Neues aus der Forschung
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Seit ihrer Erstbeschreibung vor etwa 10 Jahren haben die Antikörper gegen citrullinierte Peptidantigene (ACPA) in der Diagnostik der rheumatoiden Arthritis (RA) stark an Bedeutung gewonnen. Ihr früher Nachweis und die hohe Spezifität bei vergleichbarer Sensitivität machen sie dem Rheumafaktor deutlich überlegen. Allerdings scheinen sie weniger gut geeignet, den Therapieerfolg zu belegen sowie extraartikuläre Manifestationen und Krankheitsaktivität vorherzusagen. Aktuelle Forschungsansätze nutzen ACPA, um die Pathogenese der RA detaillierter aufzuklären.

Abstract

Since their original description ten years ago, antibodies against citrullinated peptide antigens (ACPA) have become increasingly important in the diagnosis of rheumatoid arthritis (RA). They are now considered superior to the rheumatoid factor because they can be detected earlier in the course of the disease and are more specific while showing a comparable sensitivity. However, they seem to be less suitable for monitoring specific responses to therapies and for predicting extra-articular manifestations as well as disease activity. Recent research activities center around using ACPA to further elucidate the pathogenesis of RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Schellekens G, de Jong B, van den Hoogen F et al (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273–281

    Article  PubMed  CAS  Google Scholar 

  2. Girbal-Neuhauser E, Durieux JJ, Arnaud M et al (1999) The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 162:585–594

    PubMed  CAS  Google Scholar 

  3. Bang H, Egerer K, Gauliard A et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56:2503–2511

    Article  PubMed  CAS  Google Scholar 

  4. György B, Tóth E, Tarcsa E et al (2006) Citrullination: A posttranslational modification in health and disease. Int J Biochem Cell Biol 38:1662–1677

    Article  PubMed  Google Scholar 

  5. Hill J, Southwood S, Sette A et al (2003) Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 171:538–541

    PubMed  CAS  Google Scholar 

  6. Harauz G, Musse AA (2007) A tale of two citrullines-structural and functional aspects of myelin basic protein deimination in health and disease. Neurochem Res 32:137–158

    Article  PubMed  CAS  Google Scholar 

  7. Foulquier C, Sebbag M, Clavel C et al (2007) Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 56:3541–3453

    Article  PubMed  CAS  Google Scholar 

  8. Harris ML, Darrah E, Lam GK et al (2008) Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum 58:1958–1967

    Article  PubMed  CAS  Google Scholar 

  9. Renaudineau Y, Jamin C, Saraux A et al (2005) Rheumatoid factor on a daily basis. Autoimmunity 38:11–16

    Article  PubMed  CAS  Google Scholar 

  10. Mathsson L, Mullazehi M, Wick M et al (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36–45

    Article  PubMed  CAS  Google Scholar 

  11. Ursum J, Nielen M, van SD et al (2008) Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 10:R12

    Article  PubMed  Google Scholar 

  12. Szekanecz Z, Soós L, Szabó Z et al (2008) Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis: As Good as it Gets? Clin Rev Allergy Immunol 34:26–31

    Article  PubMed  Google Scholar 

  13. Lakos G, Soós L, Fekete A et al (2008) Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope. Clin Exp Rheumatol 26:253–260

    PubMed  CAS  Google Scholar 

  14. Renger F, Bang H, Fredenhagen G et al (2008) Ein POCT anti-MCV Antikörper-Assay zur Diagnose der rheumatoiden Arthritis. Z Rheumatol 67: RA2.01 (Posterabstract zum 36. DGRh)

    Google Scholar 

  15. Emery P (2006) Treatment of rheumatoid arthritis. Br Med J 332:152–155

    Article  Google Scholar 

  16. Nielen M, van Schaardenburg D, Reesink H et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386

    Article  PubMed  Google Scholar 

  17. Feist E, Egerer K, Burmester GR (2007) Autoantikörperprofile bei der rheumatoiden Arthritis. Z Rheumatol 66:212–218

    Article  PubMed  CAS  Google Scholar 

  18. Niewold TD, Harrison MJ, Paget SA (2007) Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. Q J Med 100:193–201

    CAS  Google Scholar 

  19. Innala L, Kokkonen H, Eriksson C et al (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 35:1002–1008

    PubMed  Google Scholar 

  20. Guler H, Turhanoglu AD, Ozer B et al (2008) The relationship between anti-cyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis. Scand J Rheumatol 37:337–342

    Article  PubMed  CAS  Google Scholar 

  21. Engelmann R, Brandt J, Eggert M et al (2008) IgG1 and IgG4 are the predominant subclasses among autoantibodies in RA. Rheumatology (Oxford) 47:1489–1492

    Google Scholar 

  22. Bobbio-Pallavicini F, Caporali R, Bugatti S et al (2008) What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies? J Rheumatol 35:1903–1905

    PubMed  CAS  Google Scholar 

  23. Kavanaugh A, Rosengren S, Lee S et al (2008) Assessment of rituximab’s immunomodulatory synovial effects (the ARISE trial). I: clinical and synovial biomarker results. Ann Rheum Dis 67:402–408

    Article  PubMed  CAS  Google Scholar 

  24. Bos W, Bartelds G, Vis M et al (2009) Preferential decrease of IgG4 anti-citrullinated protein antibodies during treatment with TNF blocking agents in patients with rheumatoid arthritis. Ann Rheum Dis 68:558–563

    Article  PubMed  CAS  Google Scholar 

  25. Fredenhagen G, Bang H, Descher M et al (2008) Epitop-Mapping des Anti-MCV zur Therapiekontrolle bei der rheumatoiden Arthritis. Z Rheumatol 67:RA2.03 (Posterabstract zum 36. DGRh)

    Google Scholar 

  26. Engelmann R, Brandt J, Eggert M et al (n d) The anti-mutated citrullinated vimentin response classifies RA patients into broad and narrow responders. (eingereicht)

  27. Kidd B, Ho P, Sharpe O et al (2008) Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis Res Ther 10:R119

    Article  PubMed  Google Scholar 

  28. Klareskog L, Ronnelid J, Lundberg K et al (2008) Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 26:651–675

    Article  PubMed  CAS  Google Scholar 

  29. Makrygiannakis D, Hermansson M, Ulfgren A et al (2008) Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 67:1488–1492

    Article  PubMed  CAS  Google Scholar 

  30. Verpoort KN, van Gaalen FA, van der Helm-van Mil AHM et al (2005) Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 52:3058–3062

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Die korrespondierende Autorin weist auf folgende Beziehung hin: Diese Arbeit wurde durch die Sachbeihilfe Mu 844/10-1 der DFG unterstützt.

Author information

Authors and Affiliations

  1. Institut für Immunologie der Medizinischen Fakultät, Universität Rostock, Schillingallee 70, 18057, Rostock, Deutschland

    R. Engelmann &  B. Müller-Hilke

Authors
  1. R. Engelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Müller-Hilke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Müller-Hilke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Engelmann, R., Müller-Hilke, B. Antikörper gegen citrullinierte Peptidantigene in Klinik und Forschung. Z. Rheumatol. 68, 485–490 (2009). https://doi.org/10.1007/s00393-009-0494-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-009-0494-7

Schlüsselwörter

Keywords

Search

Navigation